ABVC Biopharma Changes Certifying Accountant

TL;DR

ABVC Bio just swapped auditors, filing an 8-K today.

AI Summary

ABVC Biopharma, Inc. has filed an 8-K report on October 18, 2024, to disclose a change in its certifying accountant. The company has appointed a new independent registered public accounting firm to audit its financial statements for the fiscal year ending December 31, 2024.

Why It Matters

A change in auditor can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting, which investors should monitor.

Risk Assessment

Risk Level: medium — Changes in auditors can sometimes precede or coincide with financial restatements or other disclosures that may impact the company's valuation.

Key Players & Entities

• ABVC Biopharma, Inc. (company) — Registrant
• October 18, 2024 (date) — Filing Date
• December 31, 2024 (date) — Fiscal Year End

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar

Filing Documents

• ea0218060-8k_abvcbio.htm (8-K) — 26KB
• 0001213900-24-089013.txt ( ) — 194KB
• abvc-20241018.xsd (EX-101.SCH) — 3KB
• abvc-20241018_lab.xml (EX-101.LAB) — 33KB
• abvc-20241018_pre.xml (EX-101.PRE) — 22KB
• ea0218060-8k_abvcbio_htm.xml (XML) — 3KB

01 Changes in Registrant's

Item 4.01 Changes in Registrant's Certifying Accountant. On October 10, 2024, WWC, P.C. ("WWC"), serving as the Company's independent registered public accounting firm, has agreed not to renew its engagement with the Company. WWC's voluntary decision not to renew the engagement was approved and acknowledged by the Company's board of directors (the "Board") on October 17, 2024. The reports of WWC on the financial statements of the Company as of June 30, 2024 and for the fiscal years ended December 31, 2023 and 2022 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, other than an explanatory paragraph regarding the substantial doubt about the Company's ability to continue as a going concern. During the fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through June 30, 2024, there were no disagreements with WWC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement(s), if not resolved to the satisfaction of WWC, would have caused it to make reference to the subject matter of the disagreement(s) in connection with its report. During the fiscal years ended December 31, 2022 and 2023 and the subsequent interim period through June 30, 2024, there were no reportable events of the type described in Item 304(a)(1)(v) of Regulation S-K. The Company provided WWC with a copy of the foregoing disclosure and requested WWC to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. As of the date of this report, WWC has not agreed nor declined to provide such letter. A copy of the letter from WWC will be filed as Exhibit 16.1 by amendment immediately upon receipt of such letter duly executed by WWC. On October 17, 2024, the Board approved the engagement of Simon & Edward, LLP ("

View Full Filing

View this 8-K filing on SEC EDGAR